Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder
Objective: This post-hoc analysis examined the efficacy and tolerability of escitalopram in the prevention of relapse in Malaysian patients with obsessive-compulsive disorder. Participants and Methods: In Malaysia, 47 patients with obsessive-compulsive disorder were treated with open-label escitalop...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
2008
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/10983/1/Escitalopram_in_the_Treatment_of_Malaysian_Patients.pdf |
| _version_ | 1825719945904783360 |
|---|---|
| author | Hatim, A. Gill, J.S. Jambunathan, S.T. Yen, T.H. Ariff, M. Lemming, O.M. Azhar, M.Z. |
| author_facet | Hatim, A. Gill, J.S. Jambunathan, S.T. Yen, T.H. Ariff, M. Lemming, O.M. Azhar, M.Z. |
| author_sort | Hatim, A. |
| collection | UM |
| description | Objective: This post-hoc analysis examined the efficacy and tolerability of escitalopram in the prevention of relapse in Malaysian patients with obsessive-compulsive disorder. Participants and Methods: In Malaysia, 47 patients with obsessive-compulsive disorder were treated with open-label escitalopram (10 mg or 20 mg/day) for 16 weeks, after which the 34 responders (Yale-Brown Obsessive Compulsive Scale total decrease score, 25) were randomised to placebo or escitalopram for 24 weeks, using a double-blind protocol. Results: The primary efficacy analysis suggested a trend in favour of escitalopram treatment with respect to time to relapse (log-rank test, p = 0.07). A higher proportion of patients relapsed after placebo treatment (5 of 14, 36) than with escitalopram treatment (2 of 20, 10) Fishers exact test, 2-sided; p = 0.10. The risk of relapse was 4-fold higher for placebo than escitalopram treatment (p = 0.09). During the double-blind period, the proportion of patients reporting treatment-emergent adverse events was comparable in the 2 groups (10% in the escitalopram group vs. 14% in the placebo group); no serious events being reported. Conclusions: This post-hoc subgroup analysis suggests that escitalopram is well tolerated in Malaysian patients with obsessive-compulsive disorder and appears to confer an advantage over placebo, in terms of time to relapse and other efficacy variables. |
| first_indexed | 2024-03-06T05:27:29Z |
| format | Article |
| id | um.eprints-10983 |
| institution | Universiti Malaya |
| language | English |
| last_indexed | 2024-03-06T05:27:29Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | um.eprints-109832014-08-05T02:19:45Z http://eprints.um.edu.my/10983/ Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder Hatim, A. Gill, J.S. Jambunathan, S.T. Yen, T.H. Ariff, M. Lemming, O.M. Azhar, M.Z. BF Psychology R Medicine Objective: This post-hoc analysis examined the efficacy and tolerability of escitalopram in the prevention of relapse in Malaysian patients with obsessive-compulsive disorder. Participants and Methods: In Malaysia, 47 patients with obsessive-compulsive disorder were treated with open-label escitalopram (10 mg or 20 mg/day) for 16 weeks, after which the 34 responders (Yale-Brown Obsessive Compulsive Scale total decrease score, 25) were randomised to placebo or escitalopram for 24 weeks, using a double-blind protocol. Results: The primary efficacy analysis suggested a trend in favour of escitalopram treatment with respect to time to relapse (log-rank test, p = 0.07). A higher proportion of patients relapsed after placebo treatment (5 of 14, 36) than with escitalopram treatment (2 of 20, 10) Fishers exact test, 2-sided; p = 0.10. The risk of relapse was 4-fold higher for placebo than escitalopram treatment (p = 0.09). During the double-blind period, the proportion of patients reporting treatment-emergent adverse events was comparable in the 2 groups (10% in the escitalopram group vs. 14% in the placebo group); no serious events being reported. Conclusions: This post-hoc subgroup analysis suggests that escitalopram is well tolerated in Malaysian patients with obsessive-compulsive disorder and appears to confer an advantage over placebo, in terms of time to relapse and other efficacy variables. 2008 Article PeerReviewed application/pdf en http://eprints.um.edu.my/10983/1/Escitalopram_in_the_Treatment_of_Malaysian_Patients.pdf Hatim, A. and Gill, J.S. and Jambunathan, S.T. and Yen, T.H. and Ariff, M. and Lemming, O.M. and Azhar, M.Z. (2008) Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder. Hong Kong J Psychiatry, 18. pp. 152-157. ISSN 1026-2121, http://easap.asia/journal_file/0804_V18N4-p152-7.pdf |
| spellingShingle | BF Psychology R Medicine Hatim, A. Gill, J.S. Jambunathan, S.T. Yen, T.H. Ariff, M. Lemming, O.M. Azhar, M.Z. Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder |
| title | Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder |
| title_full | Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder |
| title_fullStr | Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder |
| title_full_unstemmed | Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder |
| title_short | Escitalopram in the treatment of Malaysian patients with Obsessive-compulsive disorder |
| title_sort | escitalopram in the treatment of malaysian patients with obsessive compulsive disorder |
| topic | BF Psychology R Medicine |
| url | http://eprints.um.edu.my/10983/1/Escitalopram_in_the_Treatment_of_Malaysian_Patients.pdf |
| work_keys_str_mv | AT hatima escitalopraminthetreatmentofmalaysianpatientswithobsessivecompulsivedisorder AT gilljs escitalopraminthetreatmentofmalaysianpatientswithobsessivecompulsivedisorder AT jambunathanst escitalopraminthetreatmentofmalaysianpatientswithobsessivecompulsivedisorder AT yenth escitalopraminthetreatmentofmalaysianpatientswithobsessivecompulsivedisorder AT ariffm escitalopraminthetreatmentofmalaysianpatientswithobsessivecompulsivedisorder AT lemmingom escitalopraminthetreatmentofmalaysianpatientswithobsessivecompulsivedisorder AT azharmz escitalopraminthetreatmentofmalaysianpatientswithobsessivecompulsivedisorder |